Ocular Therapeutix, Inc. (NASDAQ:OCUL) Director Richard L. Md Lindstrom Buys 10,000 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Director Richard L. Md Lindstrom purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 8th. The shares were acquired at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the acquisition, the director now directly owns 172,704 shares of the company’s stock, valued at $1,202,019.84. This trade represents a 6.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ocular Therapeutix Trading Up 4.7%

NASDAQ:OCUL opened at $7.39 on Tuesday. The company has a market cap of $1.18 billion, a P/E ratio of -5.60 and a beta of 1.51. Ocular Therapeutix, Inc. has a 1 year low of $4.79 and a 1 year high of $11.78. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The stock’s fifty day moving average price is $7.46 and its two-hundred day moving average price is $8.23.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The company had revenue of $17.08 million during the quarter, compared to the consensus estimate of $16.89 million. As a group, analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on OCUL shares. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a report on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price target on the stock. JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Needham & Company LLC dropped their price objective on Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, May 6th. Finally, William Blair initiated coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.25.

Institutional Trading of Ocular Therapeutix

Hedge funds and other institutional investors have recently bought and sold shares of the company. MetLife Investment Management LLC boosted its holdings in Ocular Therapeutix by 2.7% in the 4th quarter. MetLife Investment Management LLC now owns 92,734 shares of the biopharmaceutical company’s stock valued at $792,000 after purchasing an additional 2,454 shares during the period. Teacher Retirement System of Texas boosted its stake in Ocular Therapeutix by 10.0% during the fourth quarter. Teacher Retirement System of Texas now owns 27,777 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 2,526 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Ocular Therapeutix by 3.3% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,463 shares of the biopharmaceutical company’s stock valued at $755,000 after buying an additional 2,853 shares during the period. GF Fund Management CO. LTD. purchased a new position in Ocular Therapeutix during the fourth quarter worth about $28,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Ocular Therapeutix by 11.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company’s stock worth $285,000 after acquiring an additional 3,347 shares during the last quarter. Institutional investors own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.